Trial Profile
Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs UCART 19 (Primary)
- Indications Lymphoid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors IRIS; Servier
- 12 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2022 Planned End Date changed from 1 Mar 2040 to 1 Feb 2025.
- 05 Dec 2022 Planned primary completion date changed from 1 Mar 2040 to 1 Feb 2025.